Press Inquiry Form
If you are a journalist, editor, or media representative interested in covering AIMA and our innovations, please fill out the form below. We will get back to you as soon as possible.
A Tool for Diagnostic Optimization
Enhances the accuracy and speed of test interpretation.
Early Access
Suitable for those who monitor their health or are undergoing treatment.
About Aima Diagnostics
Our mission: to set the global gold standard for the interpretation of blood test results.
Every year, billions of blood tests are performed worldwide. The vast majority of them end the same way: a patient receives a page of numbers and reference ranges — and is left alone to interpret what they mean.
Some turn to search engines. Some turn to whoever explains first. Many simply disengage, and the clinical value of the test is never fully realized.
Aima Diagnostics was founded to close this gap.
We build AI-powered interpretation of laboratory results. A patient uploads their blood test results and receives a clear, structured report in plain language — covering correlations between biomarkers, patterns and abnormalities that may be difficult to identify when biomarkers are viewed individually, and personalized, evidence-based recommendations.
Not a replacement for a physician, but a bridge between raw data and informed action.
Our conviction: a laboratory test is not the product. Understanding is.
This principle shapes everything we do — from how our technology is developed to how we design every report a patient reads.
Built with clinicians, not around them
Medical AI earns trust through medical rigor.
Our interpretation approach is developed and evaluated in collaboration with physicians, researchers, and diagnostic specialists. Reports are grounded in established clinical knowledge, and our systems are designed to support clinical reasoning and decision-making — never to bypass it.
We believe the more capable medical AI becomes, the higher the standard must be for clinical validation, transparency, responsible data use, and human oversight.
From a single report to a lifetime picture
Health is not a snapshot — it is a trajectory.
Aima Diagnostics is designed to preserve each patient's longitudinal history: previous results, biomarker trends, and changes and patterns that may become relevant over time.
This continuity transforms laboratory testing from a series of disconnected events into an evolving picture of a person's health.
For clinics and laboratories, this creates new opportunities for longitudinal monitoring, repeat testing, and relationships built on value rather than discounts.
For patients, it changes something more fundamental:
they can finally understand their own data in context.
Diagnostics without borders
A laboratory report that no one understands cannot deliver its full value.
This is especially important in regions where access to physicians and specialists is limited and a page of laboratory results may be one of the few sources of medical information available to a patient.
Making interpretation more accessible — across geographies, languages, and healthcare systems — is not a side initiative at Aima Diagnostics. It is part of why we exist.
We collaborate with clinics, laboratories, universities, research institutions, and humanitarian organizations to bring AI-assisted interpretation to more people.
Because advanced medical understanding should not be limited by geography.
Where we are headed
A gold standard is not declared — it is earned, validation by validation, report by report.
We are working toward a world where every laboratory result comes with understanding attached — where a blood test is not an endpoint, but the beginning of a more informed conversation about health.
A world where laboratory data is not viewed as isolated numbers, but understood in context, connected across biomarkers, compared over time, and translated into information that patients and healthcare professionals can actually use.
That is the standard Aima Diagnostics is working to build.
Some turn to search engines. Some turn to whoever explains first. Many simply disengage, and the clinical value of the test is never fully realized.
Aima Diagnostics was founded to close this gap.
We build AI-powered interpretation of laboratory results. A patient uploads their blood test results and receives a clear, structured report in plain language — covering correlations between biomarkers, patterns and abnormalities that may be difficult to identify when biomarkers are viewed individually, and personalized, evidence-based recommendations.
Not a replacement for a physician, but a bridge between raw data and informed action.
Our conviction: a laboratory test is not the product. Understanding is.
This principle shapes everything we do — from how our technology is developed to how we design every report a patient reads.
Built with clinicians, not around them
Medical AI earns trust through medical rigor.
Our interpretation approach is developed and evaluated in collaboration with physicians, researchers, and diagnostic specialists. Reports are grounded in established clinical knowledge, and our systems are designed to support clinical reasoning and decision-making — never to bypass it.
We believe the more capable medical AI becomes, the higher the standard must be for clinical validation, transparency, responsible data use, and human oversight.
From a single report to a lifetime picture
Health is not a snapshot — it is a trajectory.
Aima Diagnostics is designed to preserve each patient's longitudinal history: previous results, biomarker trends, and changes and patterns that may become relevant over time.
This continuity transforms laboratory testing from a series of disconnected events into an evolving picture of a person's health.
For clinics and laboratories, this creates new opportunities for longitudinal monitoring, repeat testing, and relationships built on value rather than discounts.
For patients, it changes something more fundamental:
they can finally understand their own data in context.
Diagnostics without borders
A laboratory report that no one understands cannot deliver its full value.
This is especially important in regions where access to physicians and specialists is limited and a page of laboratory results may be one of the few sources of medical information available to a patient.
Making interpretation more accessible — across geographies, languages, and healthcare systems — is not a side initiative at Aima Diagnostics. It is part of why we exist.
We collaborate with clinics, laboratories, universities, research institutions, and humanitarian organizations to bring AI-assisted interpretation to more people.
Because advanced medical understanding should not be limited by geography.
Where we are headed
A gold standard is not declared — it is earned, validation by validation, report by report.
We are working toward a world where every laboratory result comes with understanding attached — where a blood test is not an endpoint, but the beginning of a more informed conversation about health.
A world where laboratory data is not viewed as isolated numbers, but understood in context, connected across biomarkers, compared over time, and translated into information that patients and healthcare professionals can actually use.
That is the standard Aima Diagnostics is working to build.
If you are a clinician, healthcare institution, diagnostic laboratory, researcher, university, or organization working to advance healthcare, we would be glad to build it with you.
Let's Build the Gold Standard Together
Tell us who you are — we'll take it from there.
A few questions to understand how we can work together — takes about a minute.
Tell us who you are — we'll take it from there.
A few questions to understand how we can work together — takes about a minute.
Aima Diagnostics — Company Information
Brand Name: Aima Diagnostics
Industry: Medical AI / HealthTech
Official Websites: www.aimamed.ai, www.aimadiagnostics.ai
Corporate Registration
United States
Norway
United States — Corporate presence, strategic partnerships, and commercial development.
Norway — Corporate presence, AI technology development, and clinical research.
Ukraine — Laboratory networks, healthcare partnerships, and clinical pilot projects.
United Kingdom — Healthcare partnerships and commercial development.
European Union — Research collaborations, technology partnerships, and market development.
Australia — Strategic target market for international expansion.
China — Medical technology integration and potential industry partnerships.
About Aima Diagnostics
Aima Diagnostics is an international medical AI technology brand with corporate entities in the United States and Norway, developing AI-powered solutions for blood test interpretation, biomarker analysis, and clinical decision support.
The company works with healthcare and research organizations and is pursuing strategic opportunities across North America, Europe, Australia, and Asia.
Brand Name: Aima Diagnostics
Industry: Medical AI / HealthTech
Official Websites: www.aimamed.ai, www.aimadiagnostics.ai
Corporate Registration
United States
- Legal Entity: Aima Diagnostics, Inc.
- Jurisdiction: Delaware, USA
Norway
- Legal Entity: Aima Diagnostics AS
- Organization Number: 937 198 140
United States — Corporate presence, strategic partnerships, and commercial development.
Norway — Corporate presence, AI technology development, and clinical research.
Ukraine — Laboratory networks, healthcare partnerships, and clinical pilot projects.
United Kingdom — Healthcare partnerships and commercial development.
European Union — Research collaborations, technology partnerships, and market development.
Australia — Strategic target market for international expansion.
China — Medical technology integration and potential industry partnerships.
About Aima Diagnostics
Aima Diagnostics is an international medical AI technology brand with corporate entities in the United States and Norway, developing AI-powered solutions for blood test interpretation, biomarker analysis, and clinical decision support.
The company works with healthcare and research organizations and is pursuing strategic opportunities across North America, Europe, Australia, and Asia.